Related Experiment Video
Updated: Apr 3, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Nomenclature and systems of classification for cardiomyopathy in children
Laura Konta1, Rodney C G Franklin2, Juan P Kaski1
11Inherited Cardiovascular Diseases Unit,Great Ormond Street Hospital,London,United Kingdom.
Insights
Cardiomyopathy classification has evolved with genetics and imaging, leading to distinct systems like AHA and ESC. Harmonization efforts aim to unify these complex diagnostic approaches for better patient care.
Area of Science:
- Cardiology
- Genetics
- Medical Classification Systems
Background:
- Cardiomyopathy classification has evolved significantly since the 1960s, driven by advancements in imaging, disease recognition, and genetic understanding.
- Early classifications focused on pathophysiological types (dilated, hypertrophic, restrictive, arrhythmogenic), later subdivided into idiopathic and disease-specific categories.
- Genetic discoveries increasingly link idiopathic cardiomyopathies to specific mutations, though genotype-phenotype correlations remain complex due to variable penetrance and age-dependent factors.
Purpose of the Study:
- To review the evolution of cardiomyopathy classification systems.
- To compare the dominant American Heart Association (AHA) and European Society of Cardiology (ESC) classification approaches.
- To discuss the challenges and recent attempts at harmonizing these systems.
Main Methods:
- Review of historical and current literature on cardiomyopathy classification.
- Analysis of the key features and differences between the AHA (2006) and ESC (2008) systems.
- Examination of the impact of genetic advances on classification.
Main Results:
- Two major classification systems, AHA and ESC, currently dominate, each with distinct criteria and subdivisions.
- The AHA system categorizes cardiomyopathies as primary (heart-focused, genetic) or secondary (systemic involvement).
- The ESC system differentiates between familial and non-familial types, excluding ion channelopathies and focusing on specific disease subtypes.
Conclusions:
- Despite differing approaches, clinical evaluation, diagnostic imaging, and genetic testing are crucial for diagnosing cardiomyopathy.
- The MOGE(S) system represents a recent attempt to harmonize existing classifications but requires further validation.
- The ongoing evolution of classification reflects the complexity of cardiomyopathies and the need for integrated diagnostic strategies.
Abstract:
There has been a progressive evolution in systems of classification for cardiomyopathy, driven by advances in imaging modalities, disease recognition, and genetics, following initial clinical descriptions in the 1960s. A pathophysiological classification emerged and was endorsed by World Health Organisation Task Forces in 1980 and 1995: dilated, hypertrophic, restrictive, and arrhythmogenic right ventricular cardiomyopathies; subdivided into idiopathic and disease-specific cardiomyopathies. Genetic advances have increasingly linked "idiopathic" phenotypes to specific mutations, although most linkages exhibit highly variable or little genotype-phenotype correlation, confounded by age-dependent changes and varying penetrance. The following two dominant classification systems are currently in use, with advocates in both continents. First, American Heart Association (2006): "A heterogeneous group of diseases of the myocardium associated with mechanical and/or electrical dysfunction that usually exhibit inappropriate ventricular hypertrophy or dilatation due to a variety of causes that frequently are genetic". These are subdivided to those predominantly involving the heart - primary - due to genetic mutation, including ion channelopathies, acquired disease, or mixed; and those with systemic involvement in other organ systems - secondary. Second, European Society of Cardiology (2008): "A myocardial disorder in which heart muscle is structurally and functionally abnormal… sufficient to cause the observed myocardial abnormality", with subdivision to familial and non-familial, excluding ion channelopathies, and split to specific disease subtypes and idiopathic. Further differences exist in the definitions for hypertrophic cardiomyopathy; however, whichever high-level classification is used, the clinical reality remains phenotype driven. Clinical evaluation and diagnostic imaging dominate initial patient contact, revealing diagnostic red flags that determine further specific tests. Genetic testing is undertaken early. A recent attempt to harmonise these competing systems named the MOGE(S) system, based on descriptive logical nosology, currently remains unproven as a fully practical solution.
More Related Videos
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure IV: Classification and Diagnostic Evaluation
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy

